10.01.02
Interleukin Genetics Signs Letter of Intent
Interleukin Genetics (ILGN), Waltham, MA, has signed a letter of intent with an undisclosed major consumer products company to develop and market proprietary genomics-based nutritional and skincare products. The two parties have executed a letter of intent that, in exchange for an undisclosed sum, permits the nutrition company a limited period in which to evaluate the option of entering into a joint venture or executing a licensing agreement in the area of nutritional genomics. The arrangement allows ILGN to continue its business development activities for the diagnostic and therapeutic applications of the company's technology.
Interleukin Genetics (ILGN), Waltham, MA, has signed a letter of intent with an undisclosed major consumer products company to develop and market proprietary genomics-based nutritional and skincare products. The two parties have executed a letter of intent that, in exchange for an undisclosed sum, permits the nutrition company a limited period in which to evaluate the option of entering into a joint venture or executing a licensing agreement in the area of nutritional genomics. The arrangement allows ILGN to continue its business development activities for the diagnostic and therapeutic applications of the company's technology.